Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study

OBJECTIVE: Mycophenolate mofetil (MMF) is an established therapy for systemic sclerosis (SSc), but its pharmacokinetics in this disease remains unexplored. We have investigated drug exposure in MMF-treated patients with SSc in relation to clinical features of the disease and common concomitant drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Andréasson, Kristofer, Neringer, Karl, Wuttge, Dirk M., Henrohn, Dan, Marsal, Jan, Hesselstrand, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539387/
https://www.ncbi.nlm.nih.gov/pubmed/33023643
http://dx.doi.org/10.1186/s13075-020-02323-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539387/
https://www.ncbi.nlm.nih.gov/pubmed/33023643
http://dx.doi.org/10.1186/s13075-020-02323-8

Ejemplares similares